profit from every ₪100 of sales.
₪0₪100
Danel (Adir Yeoshua)
₪412.10-0.79% today
-11.6% in 1 year
1-year low ₪381.801-year high ₪496.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
You pay ₪21.02 for every ₪1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Danel (Adir Yeoshua) vs. similar companies
Danel (Adir Yeoshua) grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from ₪100 of sales | Sales growth a year | Price per ₪1 of profit |
|---|---|---|---|
| Danel (Adir Yeoshua) | 21.0× · Fair price | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.7× · Fair price | ||
 IHH Healthcare Berhad | 33.3× · Expensive | ||
 Rede D'Or São Luiz | 15.8× · Fair price |
AI analysis
An AI analyst reads Danel (Adir Yeoshua)'s last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- 21.0×
- –
- –
- 5.5×
- 0.8×
- 17.8×
- –
- 5.6%
- 4.8%
- –
Profitability
- 18.3%
- 7.0%
- 4.0%
- –
- 19.2%
- 12.5%
- –
- –
- –
- –
Growth
- +7.1%
- −1.7%
- –
- –
- +2.1%
Financial health
- 0.5×
- 0.64
- –
- 9.8×
- 1.22
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 10%of 952
Bottom 44%of 883
Top 36%of 576
Bottom 35%of 870
Top 18%of 985
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
35No pass
Philip Fisher
38No pass
Peter Lynch
26No pass
Joel Greenblatt
47No pass
Charlie Munger
41No pass
Terry Smith
43No pass
Questions about Danel (Adir Yeoshua)
Is Danel (Adir Yeoshua) a good stock to buy?
A business with weak numbers at a fair price. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Danel (Adir Yeoshua) AI analysis
What does Danel (Adir Yeoshua) do?
Danel (Adir Yeoshua) Ltd provides human resources services in Israel. It is in Medical Care Facilities.
Is Danel (Adir Yeoshua) stock halal?
Yes. Danel (Adir Yeoshua) passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Danel (Adir Yeoshua) stock done over the past year?
Down 11.6% over the past twelve months, to ₪412.10. It traded between ₪381.80 and ₪496.00 and is 16.9% below its high.
Who are Danel (Adir Yeoshua)'s competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with Danel (Adir Yeoshua)'s.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.